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Aim: To compare the performance of HbA1c with established glucose criteria during an oral glucose
tolerance test (OGTT) and to assess HbA1c as a screening test for undiagnosed diabetes and pre-diabetes
after gestational diabetes mellitus (GDM).
Methods: Glucose homeostasis was re-evaluated 1e5 years after delivery in 140 women with previous
GDM, by means of OGTT and simultaneous HbA1c measurement. Glucose tolerance was deﬁned ac-
cording to World Health Organisation criteria. HbA1c 6.5% (48 mmol/mol) was used for diabetes
diagnosis and HbA1c 5.7% (39 mmol/mol) to deﬁne abnormal glucose homeostasis.
Results: HbA1c had low sensitivity (14.3%) and high speciﬁcity (99.1%) in diabetes diagnosis. Sensitivity
and speciﬁcity of HbA1c to detect abnormal glucose tolerance were 29.5% and 95.2%, respectively. The
consistency in classifying abnormal glucose tolerance between HbA1c and OGTT criteria was 59%
(k ¼ 0.227) and the area under the receiver operating characteristic curve was 0.708. The combined use
of HbA1c and fasting glucose criteria showed similar performance to that of fasting glucose criteria alone.
The latter identiﬁed 63% of the women with pre-diabetes or diabetes in the study cohort. However, by
lowering the cut-point of HbA1c to 5.0% (31 mmol/mol), an additional proportion (27%) with isolated
post-glucose load hyperglycaemia was identiﬁed.
Conclusion: Proposed thresholds of HbA1c had low diagnostic sensitivity. Combined with a fasting glucose
test, the performance was no better thanwith using a fasting glucose test alone. Combining a fasting glucose
test with a lower HbA1c cut-point may be an alternative approach for selection of women for an OGTT.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
HbA1c has recently been approved by the World Health Organi-
sation (WHO) as an alternative to the oral glucose tolerance test
(OGTT) for the diagnosis of diabetes mellitus outside pregnancyhe Research Funds of Malmö
rch and Development Foun-
NE-351271 and REGSKANE-
are no conﬂicts of interests
and Gynaecology, Ofﬁce for
411 995528.
sson).
Inc. This is an open access article u[1]. A diagnostic cut-point of 6.5% (48 mmol/mol) was recom-
mended based on the risk of developing microvascular complica-
tions such as retinopathy. No formal recommendations on the
interpretation of HbA1c levels below this cut-point were made.
However, the International Expert Committee (IEC) recommended
that high-risk individuals with HbA1c levels between 6.0%
(42 mmol/mol) and 6.4% (47 mmol/mol) should be considered for
diabetes prevention and interventions [2], and the American Dia-
betes Association (ADA) suggested that HbA1c levels between 5.7%
(39 mmol/mol) and 6.4% (47 mmol/mol) indicate intermediate
hyperglycaemia [3].
Womenwith gestational diabetesmellitus (GDM) are a high-risk
group for development of type-2 diabetes [4]. According to Swedish
national guidelines, lifestyle intervention and follow-up of these
women after pregnancy should have high priority, but it is not clear
whichmeasures should be followed. In the primary care setting, thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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practical, possibly in combination with a fasting glucose test. Both
are quick and easy to perform, are more convenient for and
acceptable to patients, and are less expensive than the OGTT [5].
Using the slightly modiﬁed European Association for the Study
of Diabetes criteria, deﬁning GDM as a 2-h capillary blood glucose
concentration of 9.0 mmol/l during a universal 75-g OGTT [6], the
estimated prevalence of GDM in southern Sweden over the past
decade has increased from 1.9 to 2.6% [7]. In a previous study from
our area, it was reported that 30% of the women with GDM in the
study cohort had developed diabetes 5 years after delivery [8].
Furthermore, fasting blood glucose levels of 5.2 mmol/l and
HbA1c levels of 5.7% (38 mmol/mol) during pregnancy were
found to be associated with a four-to six-fold increased risk.
The aim of the present study was to compare the performance of
HbA1c testing with that of established glucose criteria during the
OGTT at 1- to 5-year follow-up post-partum in this historical cohort
of womenwith GDM, and to assess HbA1c as a screening test (alone
or combined with a fasting glucose test) for undiagnosed diabetes
and abnormal glucose tolerance.
Material and methods
All womenwho are diagnosed with GDM in the region of Malmö
and Trelleborg in southern Sweden are referred to the Department
of Endocrinology in Malmö for follow-up during pregnancy.
Women referred between 1996 and 1999 were invited to take part
in a 5-year follow-up program, including measurement of HbA1c
and a 75-g OGTT at 1, 2, and 5 years after delivery. The study design
has been described previously in detail [8]. Of 182 eligible women, a
total of 174 were ﬁnally included. Only women with complete
glucose data at follow-up, i.e. simultaneous measurements of
fasting and 2-h glucose values during the OGTT, in addition to an
HbA1c test, were selected for the present evaluation. Altogether,
122womenwith complete glucose data attended the 1-year follow-
up, 84 attended the 2-year follow-up, and 55 attended the 5-year
follow-up. Since the incidence of type-2 diabetes is known to in-
crease cumulatively within the ﬁrst 1e5 years after GDM in preg-
nancy, we used the latest available set of complete glucose data
from each woman for the present evaluation to ensure the longest
possible follow-up time [9]. We also wanted to minimize the risk of
selection bias by using data taken from the same woman on several
occasions. Accordingly, the ﬁnal evaluation was based on data from
55 women at 5-year follow-up, 48 women at 2-year follow-up, and
37 women at 1-year follow-up.
Of the 140 women who were included, 72 (51%) were of Nordic
origin (all but two of them Swedish). Women of non-Nordic origin
were immigrants from different countries in Southern and Eastern
Europe, Asia, South America, and Africa, with Arabwomen form the
Middle East (17%) and women from former Yugoslavia (10%)
comprising the largest groups.
A standard 75-g OGTT was performed after overnight fasting. A
Venﬂon catheter (Becton Dickinson, Helsingborg, Sweden) was
inserted into an antecubital vein. Blood samples were drawn in
duplicate at 0 and 120 min for determination of glucose concen-
trations, and the mean value was calculated. A blood sample for
determination of HbA1c was collected in an EDTA-containing tube.
Weight and height were recorded and body mass index (BMI) was
calculated.
Based on the results of the OGTTs, four subgroups were deﬁned
according to theWHO (1999) criteria: (1) normal glucose tolerance,
fasting blood glucose (FBG) <5.6 mmol/l, and 2-h blood glucose (2-
h BG) <6.7 mmol/l; (2) impaired fasting glucose (IFG), FBG 5.6e
6.0mmol/l, and 2-h BG<6.7mmol/l; (3) impaired glucose tolerance
(IGT), FBG <6.1 mmol/l, and 2-h BG 6.7e9.9 mmol/l; and (4)diabetes mellitus, FBG6.1 mmol/l, and/or 2-h BG10mmol/l [10].
Glucose homeostasis was also determined based on HbA1c levels
according to the WHO and ADA recommendations;  6.5%
(48mmol/mol) suggesting diabetes; 5.7e6.4% (39e47mmol/mol)
suggesting high risk (pre-diabetes); and <5.7% (<39 mmol/mol)
suggesting normal glucose homeostasis [1,3]. For comparison, the
combined category “IFG and IGT” was used to represent pre-
diabetes and the combined category “IFG, IGT, and diabetes” was
used to represent abnormal glucose tolerance. Similarly, HbA1c
levels of 5.7% (39 mmol/mol) were used to deﬁne abnormal
glucose homeostasis.
Informed consent was obtained from all participants, and the
study protocol was approved by the Ethics Committee of Lund
University.
Assays
The HemoCue glucose system (HemoCue AB, Ängelholm, Swe-
den) was used for immediate measurement of whole blood glucose
concentrations (in mmol/l). The mean coefﬁcient of variation (CV)
of the duplicate analyses performed in this study was 3.1% for
fasting samples and 1.9% for 2-h samples. HbA1c was analyzed by
ion-exchange chromatography, Mono S-HPLC [11]. The within-
assay CV (on the Mono S scale) of this method is 0.47e0.94% and
the between-assay CV is 1.68%. The Mono S method, together with
the reference method from NGSP, is a designated comparison
method in the IFCC (International Federation of Clinical Chemistry)
Reference System [12]. Numbers given in % (Mono S) were con-
verted to NGSP units (%) and IFCC units (mmol/mol) using the
regression equations developed by the IFCC Working Group [12].
Statistical analysis
The agreement between diagnoses resulting from HbA1c and
OGTT criteria was estimated by constructing cross tables. The
k coefﬁcient (k) was calculated, where the closer the value is to 1,
the better the agreement [13]. Spearman’s correlation was used to
analyze the relationship between glucose and HbA1c values. A
receiver operating characteristic (ROC) curve was constructed for
HbA1c using OGTT as the gold standard for the diagnosis of
abnormal glucose tolerance, and the area under the curve (AUC)
was calculated. Diagnostic accuracy was assessed using sensitivity,
speciﬁcity, positive predicted value (PPV), and negative predictive
value (NPV).
Statistical analyses were performed with IBM SPSS Statistics 22
for Windows (IBM Corporation, New York, NY). Any p-value of less
than 0.05 was considered statistically signiﬁcant.
Results
Mean (SD) values for age and BMI of the women included were
35.4  5.6 years and 26.6  2.3 kg/m2, respectively. A median
(interquartile range) of 26 (21e60) months had elapsed since their
GDM pregnancy. Based on the OGTT, 62 women (44.3%) had normal
glucose tolerance, 50 (35.7%) had pre-diabetes (13 IFG, 37 IGT), and
28 (20.0%) had diabetes. Among the 37 womenwith IGT, 12 had FBG
values within the IFG range. In 8 women, the diagnosis of diabetes
was based on the 2-h glucose value alone and in 6 women it was
based on the fasting glucose value alone. In contrast, using the
HbA1c criteria for deﬁnition, the corresponding ﬁgures for normal
glucose homeostasis, pre-diabetes, and diabetes were 114 (81.4%),
21 (15.0%), and 5 (3.6%), respectively. In four of the ﬁve HbA1c tests
that were consistent with a diagnosis of diabetes, the OGTT
revealed diabetes, and in the remaining test it revealed IGT. The
sensitivity of HbA1c for diabetes diagnosis was 14.3% and the
Table 1
Cross-tabulation between HbA1c, fasting blood glucose, and oral glucose tolerance
test criteria in categorization of abnormal glucose metabolism
Test criteria Normal
OGTT
Abnormal
OGTT
HbA1c 5.7% (39 mmol/mol) 3 23
HbA1c <5.7% (<39 mmol/mol) 59 55
FBG 5.6 mmol/l 0 49
FBG <5.6 mmol/l 62 29
HbA1c 5.7% (39 mmol/mol) or
FBG 5.6 mmol/l
3 52
HbA1c <5.7% (<39 mmol/mol) and FBG
<5.6 mmol/l
59 26
FBG, fasting blood glucose; OGTT, oral glucose tolerance test.
Figure. 1. Receiver operating characteristic curve for HbA1c for detection of abnormal
glucose tolerance by the oral glucose tolerance test. The optimal cut-off point of HbA1c
is indicated.
R. Claesson et al. / Journal of Clinical & Translational Endocrinology 2 (2015) 21e25 23speciﬁcity was 99.1%. The agreement between HbA1c and OGTT in
classifying diabetes or non-diabetes was poor, as indicated by a
k coefﬁcient of 0.194.
Altogether 23 of 140 women (16.4%) met the combined criteria
for abnormal glucose tolerance (both OGTT criteria and HbA1c
criteria) (Table 1). The consistency in classifying abnormal glucose
tolerance between HbA1c and OGTT criteria was 59% (82/140) and k
was 0.227, indicating poor agreement. Similar results were obtained
when evaluating Nordic and non-Nordic women as separate groups
(k 0.278 and k 0.166, respectively), or when evaluating the 1-, 2- and
5-year results separately (k 0.260, k 0.072 and k 0.337, respectively).
Combining HbA1c criteria with fasting glucose criteria improved
the agreement for the total group to fair (79%, k ¼ 0.596), although
it was no better than between FBG criterion alone and OGTT criteria
(79%, k ¼ 0.599).
Correlations of HbA1c with FBG were 0.353 (p < 0.001) at 1- to
2-year follow-up and 0.613 (p < 0.001) at 5-year follow-up. The
corresponding ﬁgures for HbA1c versus 2-h glucose were 0.380
(p < 0.001) and 0.430 (p < 0.001), respectively.
An ROC curve was constructed to evaluate the sensitivity and
speciﬁcity of HbA1c in detection of abnormal glucose tolerance, as
deﬁned by the OGTT (Fig. 1). The optimal cut-off point of HbA1c for
predicting abnormal glucose tolerance was 5.2% (33 mmol/mol)
(AUC ¼ 0.708, 95% CI 0.624e0.793), sensitivity was 69.2%, and
speciﬁcity was 59.7%.
Table 2 shows the sensitivity, speciﬁcity, PPV, and NPV of HbA1c
and FBG, or a combination of both diagnostic tests, relative to the
OGTT (the gold standard) for various cut-offs. Overall, the FBG test
alone showed better performance than the HbA1c test alone in
detecting abnormal glucose tolerance. Of those who screened
positive using the FBG test alone, all had (by deﬁnition) abnormal
glucose tolerance (13 IFG, 12 IGT, 24 diabetes), as compared to 32%
of those who screened negative (25 IGT, 4 diabetes). The combined
use of HbA1c and FBG criteria showed performance similar to that
with use of the FBG test alone.
We then tested a combination of FBG (5.6 mmol/l) with
various cut-points of HbA1c to increase the sensitivity and NPV of
the combined test. From this, HbA1c 5.0% (31 mmol/mol) wasTable 2
Diagnostic indices of various criteria using HbA1c or fasting blood glucose to detect abn
Diagnostic test na Sen
HbA1c 5.7% (39 mmol/mol) 26 29.
FBG 5.6 mmol/l 49 62.
HbA1c 5.7% (39 mmol/mol) or FBG 5.6 mmol/l 55 66.
HbA1c 6.0% (42 mmol/mol) 17 21.
HbA1c 6.0% (42 mmol/mol) or FBG 5.6 mmol/l 51 65.
HbA1c 5.0% (31 mmol/mol) 103 83.
HbA1c 5.0% (31 mmol/mol) or FBG 5.6 mmol/l 108 89.
FBG, fasting blood glucose; PPV, positive predictive value; NPV, negative predictive valu
a Number of women who met cut-off values.judged as an optimal cut-point, according to which, in addition to
the 49 women who screened positive by FBG criterion alone,
another 59 women were identiﬁed (38 with normal glucose toler-
ance, 17 with IGT, and four with diabetes by OGTT). Of the
remaining 32 women who screened negative using this combina-
tion, 8 had abnormal glucose tolerance (all IGT) by OGTT.
Discussion
In this historical cohort of women who had had GDM and who
were prospectively followed for up to 5 years after delivery, we
found suboptimal performance of proposed cut-points of HbA1c
relative to OGTT in diagnosis of diabetes and abnormal glucose
tolerance post-partum. Combined with a fasting glucose test, the
diagnostic accuracy improveddalthough to an extent similar to
that obtained using the fasting glucose test alone.
Women with a history of GDM have a 7.7-fold increased risk of
future development of type-2 diabetes [4]. It has been shown pre-
viously that lifestyle intervention can prevent or delay the onset of
type-2 diabetes inwomenwith IGT and a history of GDM [14]. Thus,
re-evaluation after pregnancy is essential. However, studies have
repeatedly shown poor compliance with recommended guidelines
in clinical practice, and the women fail to attend the post-partum
visit, even in a research setting [15e18]. Easy, cost-effective, andormal glucose tolerance
sitivity (%) Speciﬁcity (%) PPV (%) NPV (%)
5 95.2 88.5 51.8
8 100.0 100.0 68.1
7 95.2 94.5 69.4
8 100.0 100.0 50.4
4 100.0 100.0 69.7
3 38.7 63.1 64.9
7 38.7 64.8 75.0
e.
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many women as possible who are at risk of type-2 diabetes. In this
context, the HbA1c test appears to be attractive and its validity as a
screening tool for abnormal glucose metabolism after GDM has
only been examined in a few studies, with somewhat conﬂicting
results [17,19e22].
Using the HbA1c test alone, we found that less than 5% of the
women classiﬁed as having normal glucose tolerance by OGTT
criteria would be misclassiﬁed as having abnormal glucose ho-
meostasis, and more importantly, that 71% of the women classiﬁed
as having abnormal glucose tolerance by OGTT criteria would be
misclassiﬁed as having normal glucose homeostasis. Proposed cut-
points of HbA1c had low sensitivity and modest NPV in detection of
any degree of abnormal glucose tolerance, and therefore do not
appear to be suitable for screening in these women. However,
because of high PPV and high speciﬁcity, it may be used as a
conﬁrmatory test of the actual glucose tolerance status. The FBG
test criterion had moderate sensitivity and NPV in detection of
abnormal glucose tolerance. Megia et al. reported almost identical
results to ours regarding HbA1c for diabetes diagnosis, with a
sensitivity of 16.7% and a speciﬁcity of 100% [19]. However, using
HbA1c of 5.7 (39 mmol/mol) as cut-off for any kind of impaired
glucose tolerance, the sensitivity was comparatively low (13.5%). In
contrast, Katreddy et al. reported a sensitivity of 71% and a speci-
ﬁcity of 99% (AUC 0.98) in the diagnosis of diabetes, although the
sensitivity of HbA1c6.0% (42mmol/mol) for detecting abnormal
glucose tolerance was low (28%) [20]. Another study by Kim et al.,
based on a small group of women who had had GDM, found a
sensitivity 65% and a speciﬁcity 68% for HbA1c  5.7% (39 mmol/
mol) in detection of abnormal glucose tolerance [21]. ROC curves
gave results similar to ours, with an AUC for any degree of impaired
glucose tolerance of 0.76.
In line with previous studies, we found poor agreement in the
consistency between HbA1c and OGTT criteria in classifying dia-
betes and abnormal glucose tolerance post-partum, although cor-
relations between HbA1c and glucose values obtained during the
OGTT indicated fairly good agreement [17,19,21].
Basedon thepresentﬁndings, the combination ofHbA1c and FBG
criteria classiﬁed 33% of the women who were classiﬁed as having
abnormal glucose tolerance by OGTT criteria, as having normal
glucose homeostasis. The speciﬁcity and PPV were high, but this
combination did not improve the sensitivity and speciﬁcity obtained
by FBG criterion alone. Similar observations for the combined test
relative to the fasting glucose test alone were made by Picon et al.
and Megia et al., albeit with higher sensitivities (83% and 82%,
respectively),whichmight in turn be partly explained by their use of
somewhat lower cut-offs [17,19]. Predictive values were only re-
ported in the study by Picon et al., who found an NPV of 85%. Noctor
et al. used a similar approachwith cut-offs identical to those used by
Picon et al., and reported sensitivity of 90% and NPV of 97% in
detecting abnormal glucose tolerance, thereby reducing the pro-
portion of women requiring conﬁrmatory testing to 31%, as
compared to 29% in the study byMegia et al. and 47% in the study by
Picon et al. [22].
There are several plausible explanations for the discrepant re-
sults between studies. Firstly, differences in diagnostic criteria for
the diagnosis of GDM imply that more or less high-risk womenwill
be identiﬁed, rendering comparisons less reliable. If high glucose
cut-points are used more severely affected womenwill be selected.
We have recently evaluated how the introduction of the new In-
ternational Association of the Diabetes and Pregnancy Study
Groups (IADPSG) criteria and the 1999 WHO criteria would affect
the prevalence of GDM in our population [23]. The results indicate
that 26% more women would be identiﬁed by the IADPSG criteria
and 20% more women by the WHO criteria, compared with themodiﬁed EASD criteria presently in use. The prevalence of
abnormal glucose tolerance post-partum observed in the present
study was relatively high (55.7%) in comparison with other studies,
ranging from18.4% in the study by Noctor et al. to 68.5% in the study
by Kim et al. This could partly be attributed to the different glucose
cut-points used for the diagnosis of GDM. Differences in the interval
to post-partum retesting between studies would also affect the
results. Median interval to follow-up in the present study was 2.1
years as compared with 3 months (Megia et al.), 1 year (Picon et al.),
1.5 years (Kim et al.) and 2.6 years (Noctor et al.). Other important
differences include patient characteristics, such as BMI and age, and
the ethnic composition of the cohorts, which in turn may have an
impact on the interpretation of HbA1c data per se [24]. Also, the
HbA1c assays used may differ and may not be fully comparable.
The rationale for recommending OGTT post-partum in women
with GDM is not only to detect women with apparent diabetes but
also to identify womenwith pre-diabetes and IGT inwhom diabetes
can be delayed or prevented [14,25]. We therefore hypothesized
that a reasonable screening model would be to accept all women
with IFG for intensive follow-up and prevention without retes-
tingdin our sample, corresponding to 35% of the study population
(49/140). If we then accept HbA1c 5.0% (31 mmol/mol) as a cut-off
for further identiﬁcation, that would leave 59 women for conﬁr-
matory testing by OGTT, among whom 36% (21/59) would be
diagnosed with diabetes or IGT based on the 2-h glucose value
alone. Of the remaining 32 women, 25% would be misclassiﬁed as
having normal glucose metabolism, i.e. 10% (8/78) of the women
with any kind of abnormal glucose tolerance in the study cohort.
Several limitations of this studymust be considered. Since it was
based on historical data, the results may not be completely repre-
sentative of the contemporary population. Furthermore, glucose
concentrations were determined in whole blood, which was the
routine in Sweden at the time of the study. Converted glucose
thresholds provided by the WHO (1999) for whole blood were used
for classiﬁcation. Due to the higher water concentration in plasma
than erythrocytes, glucose concentration in plasma is higher than
glucose in whole blood. A constant factor of 1.11 for the conversion
between concentration of glucose in blood and the equivalent con-
centration in plasma is recommended, assuming a normal hemato-
crit [26]. Since the concentration of glucose inwhole blood depends
on the hematocrit the WHO conversion tables may be inaccurate in
some situations.We have no information on the hematocrit in these
women, but they were all apparently healthy and we do not believe
this should have any major impact on the results. One further limi-
tation of the study is that each testwas only performed once and the
diagnosis of diabetes was not conﬁrmed by a repeat test. Moreover,
hemoglobinopathies were not systematically assessed but are
generally more common in the Mediterranean and not-white pop-
ulations. However, the agreement between HBA1c and OGTT results
didnotmarkedly improvebyexcludingnon-Nordicwomen fromthe
evaluation (k 0.278 as compared with k 0.227).
This is the ﬁrst study in Sweden comparing the performance of
HbA1c with that of established glucose criteria during the OGTT in
women with previous GDM. The strengths of the study include the
prospective design with long-term follow-up of a relatively large
number of women after GDM pregnancy. The uniform diagnostic
procedure for GDM used in southern Sweden since 1995 is also
noteworthy: it is based on a universal 75-g OGTT and there have
been no major changes. Furthermore, the HbA1c assay used has a
known and constant relation to the IFCC standard [12].
In summary, proposed thresholds of HbA1c (6.5% [48 mmol/
mol] and5.7% [39mmol/mol]) had low sensitivity in diagnosis of
diabetes and abnormal glucose tolerance in the present study
cohort. Combined with a fasting glucose test, the performance was
no better than using a fasting glucose test alone. Considering that
R. Claesson et al. / Journal of Clinical & Translational Endocrinology 2 (2015) 21e25 25early detection of pre-diabetes is of utmost importance in these
women to prevent the development of diabetes, combining a fasting
glucose test with a lower cut-point of HbA1c may be an alternative
approach to select women for an OGTTdto identify those who have
isolatedpost-glucose loadhyperglycaemia.With anHbA1c cut-off of
5.0% (31 mmol/mol), the number of women who would need a
conﬁrmatory OGTT decreased by almost 60%, thus overlooking 10%
of those with abnormal glucose tolerance in the study cohort.
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